Posted on 25/06/2009 in Pharmaceutical Company Product News UCB is committed to improving the lives of those who suffer from serious central nervous system (CNS) diseases, it has stated.
Along with Jazz Pharmaceuticals, the company has been analysing the potential of sodium oxybate (JZP-6) for the treatment of fibromyalgia.
Results from the second of two phase III clinical trials confirm the positive findings from the first investigation.
The medication significantly decreased fatigue and pain, as well as improved daily functions.
Chief medical officer at UCB Iris Loew-Friedrich explained the company is dedicated to helping people who suffer from such illnesses.
"The positive results of the two Phase III trials are encouraging and suggest that subject to regulatory approval, this may offer a new treatment option for people with fibromyalgia," she said.
Lead investigator of the first study Dr I Jon Russell added sufferers of the chronic disease experience psychological distress and widespread pain, among other symptoms.
In May, the European Medicines Agency's committee for medicinal products for human use granted UCB's Neupro (rotigotine transdermal patch) a positive opinion for use in Europe.Other news stories from 25/06/2009
Read more in the Zenopa News Archive
How this news is generated
|
